Management of Acute Exacerbation of Bronchial Asthma

First-Line Treatment for Acute Asthma Exacerbations

The American College of Allergy, Asthma, and Immunology recommends short-acting β2-agonists (SABAs) like levosalbutamol/albuterol as the treatment of choice for relief of acute asthma symptoms due to their rapid bronchodilating effect 1, 2
SABAs provide rapid, dose-dependent bronchodilation with minimal side effects, making them ideal for emergency situations 3
Ipratropium bromide (anticholinergic) provides additive benefit to SABAs in moderate or severe exacerbations, particularly in emergency care settings 1, 4
The combination of SABA and ipratropium has been shown to reduce hospitalizations, especially in patients with severe airflow obstruction 4

Multiple high doses of ipratropium bromide added to β2-agonist therapy increases bronchodilation in acute settings 4

Long-acting β2-agonists (LABAs) like formoterol are primarily indicated for long-term control and prevention of symptoms in persistent asthma, not for acute relief 1, 2
LABAs are not recommended as monotherapy for asthma and should be used in combination with inhaled corticosteroids (ICS) for maintenance therapy 1, 2
While formoterol has a relatively quick onset compared to other LABAs, it is still not as rapid as SABAs for emergency situations 1

For acute exacerbations, administer high doses of SABA via MDI with valved holding chamber or nebulizer 4
Add multiple high doses of ipratropium bromide to the SABA therapy to increase bronchodilation 4
Continuous administration of β2-agonists may be more effective than intermittent administration in patients with severe exacerbations 3
Systemic corticosteroids should be administered early in moderate-to-severe exacerbations to address the inflammatory component 4, 3

Nebulizer therapy might be preferred for patients unable to cooperate effectively with MDI use due to age, agitation, or severity of exacerbation 4
Monitor patients for response to treatment through subjective response, physical findings, and objective measures like FEV1 or PEF 4
Response to treatment in the emergency department is a better predictor of need for hospitalization than the severity of exacerbation at presentation 4

The National Asthma Education and Prevention Program (NAEPP) recommends using albuterol combined with ipratropium bromide as the rescue regimen for acute asthma exacerbations, rather than budesonide/formoterol. 5
Short‑acting β₂‑agonist albuterol is the first‑line agent for acute exacerbations because it provides rapid, dose‑dependent bronchodilation with minimal side effects. 5
A high dose of ipratropium bromide (0.5 mg nebulized solution or 8 puffs via metered‑dose inhaler in adults) should be added to each albuterol dose to enhance bronchodilation. 5
The albuterol + ipratropium combination has been shown to reduce hospital admissions, especially in patients with severe airflow limitation. 5
Compared with albuterol alone, the albuterol + ipratropium regimen yields a modest but clinically meaningful improvement in lung‑function measurements. 6

Initial rescue therapy consists of three albuterol treatments administered every 20–30 minutes. 5
Albuterol can be delivered either by metered‑dose inhaler with a valved holding chamber (4–12 puffs per dose) or by nebulizer; nebulization is preferred when the patient is unable to cooperate with an inhaler. 5
Ipratropium bromide should be added to each albuterol treatment (0.5 mg nebulized or 8 puffs via inhaler). 5

In patients whose forced expiratory volume in 1 second (FEV₁) or peak expiratory flow (PEF) is less than 40 % of predicted, continuous albuterol infusion is recommended, as it may be more effective than intermittent dosing. 6

Systemic corticosteroids should be administered early (within the first hour) to all individuals with moderate‑to‑severe exacerbations to address airway inflammation and lower hospitalization rates. 5
The anti‑inflammatory benefits of systemic steroids become apparent after 6–12 hours, underscoring the importance of prompt administration. 6

Budesonide/formoterol (SMART) is a maintenance therapy designed to reduce future exacerbations; it is not appropriate for immediate relief in the emergency setting. Patients should continue their controller medication but rely on albuterol + ipratropium for acute rescue. 5